Glenmark reduces generic version of Covid-19 drug favipiravir price to Rs 75


Glenmark Pharmaceuticals Ltd said today it would lower the price of its generic version of favipiravir, FabiFlu, to 75 rupees per tablet in India. The drug is for restricted emergency use in patients with mild-to-moderate Covid-19 symptoms.


"Glenmark's price reduction aims to make FabiFlu further accessible for Covid-19 patients across the country," the company said in a statement.


Meanwhile, Japanese researchers on Friday said a clinical trial of Fujifilm's Avigan yielded inconclusive results as a treatment for Covid-19.

Dr.Reddy's Laboratories Ltd has entered into a deal with Fujifilm to sell Avigan globally excluding Japan, China and Russia.